Clinical Trials
18 trialsNCT01625351 2026-02-06
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
Phase 1 Completed
NCT04812470 2025-09-22
HAITILS
Vastra Gotaland Region
Phase 1 Completed
NCT07183852 2025-09-19
GoTIL-01
Vastra Gotaland Region
Phase 1 Not yet recruiting
NCT05893654 2025-09-15
MELCOM
Hospital das ClÃnicas de Ribeirão Preto
Phase 1/2 Enrolling by invitation
NCT05903937 2023-06-15
HAITILS-PHP
Vastra Gotaland Region
Phase 1 Not yet recruiting
NCT00324727 2021-06-21
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
Delcath Systems Inc.
Phase 3 Completed
NCT01323517 2018-05-15
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002973 2015-10-02
Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma
University of Wisconsin, Madison
Phase 2 Completed
NCT02507076 2015-07-23
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
Albert Einstein College of Medicine
Phase NA Withdrawn
NCT00661336 2015-03-13
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
Duke University
Phase 1 Withdrawn
NCT00565968 2015-03-06
Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg
Duke University
Phase 1 Completed
NCT01531244 2014-07-18
Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma
Washington University School of Medicine
Phase 1/2 Withdrawn
NCT00096083 2013-10-23
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Delcath Systems Inc.
Phase 2 Completed
NCT00003789 2013-07-16
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
National Cancer Institute (NCI)
Phase 3 Completed
NCT00004250 2013-01-16
Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00421811 2010-12-28
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
Adherex Technologies, Inc.
Phase 1/2 Completed
NCT00001296 2008-03-04
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
National Institutes of Health Clinical Center (CC)
Phase 3 Completed
NCT00001577 2008-03-04
Pilot Study of a Double Isolation Perfusion Schedule Using Melphalan Alone for Intransit Melanoma or Unresectable Sarcoma of the Extremity
National Institutes of Health Clinical Center (CC)
Phase 1 Completed